Launch of the new system is part of the company’s mission to deliver an enhanced platform combining advanced imaging, digital health informatics, and improved patient outcomes
Mauna Kea Technologies today unveiled the next-generation Cellvizio platform, which has already received both 510(k) clearance (K193416) from the U.S. Food and Drug Administration (FDA) and CE marking. Built with enhanced capabilities, this entirely new system uses the company’s proprietary Confocal Laser Endomicroscopy (CLE) advanced imaging technology to deliver cellular and molecular imaging virtually anywhere in the human body, and will be available for purchase in the second half of 2021.
Building upon the success of the previous models, the new generation of Cellvizio equips physicians with the most advanced cellular imaging technology to improve patients’ lives. The platform includes several new features: an all-new workflow integration for endoscopic, bronchoscopic, or operating environments via integrated connectivity; enhanced capabilities enabling artificial intelligence (AI) for assisted pattern recognition; and a small footprint and slim profile allowing easy maneuverability within the procedure room.
“Our next-generation platform represents a tremendous leap forward in product innovation that significantly improves the ease of integrating Cellvizio into procedure rooms around the world,” said Robert L. Gershon, Chief Executive Officer of Mauna Kea Technologies. “The system readiness to host novel advanced capabilities, particularly artificial intelligence, will expand our ability to provide advanced imaging techniques and real-time digital health informatics as part of the overall delivery of patient care.”
Learn more by visiting: www.landing.maunakeatech.com/next-gen-cellvizio
